Bill Title: To nullify modifications made by the Food and Drug Administration on January 3, 2023, to the risk evaluation and mitigation strategy under section 505-1 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355-1) for mifepristone, and for other purposes.

Spectrum: Partisan Bill (Republican 2-0)

Status: (Introduced) 2023-10-06 - Referred to the Subcommittee on Health. [HB5850 Detail]

---

Bill Drafts

Revision	Date	Format	Source	View
Introduced	2023-10-05	PDF	Link	View

Amendments

Amendment	Date	Disposition	Format	Source	View
No bill amendments currently on file for US Congress HB5850

Supplemental Documents

Title	Description	Date	Format	Source	View
No supplemental documents for US Congress HB5850 currently on file.

Social Comments on US HB5850